Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Shah N et al. Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14570. [Epub ahead of print].
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Sborov DW et al. Leuk Lymphoma. 2017 Mar 7:1-9. doi: 10.1080/10428194.2017.1298751. [Epub ahead of print].